Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nivolumab and NSCLC

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    96 result(s) found for: Nivolumab and NSCLC. Displaying page 3 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2016-001835-11 Sponsor Protocol Number: CA018-001 Start Date*: 2017-02-01
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (Master Protocol Revised version 02 dated 27-Jul-2016 + S...
    Medical condition: Advanced Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003454-83 Sponsor Protocol Number: 2019IN01 Start Date*: 2019-12-20
    Sponsor Name:Amsterdam UMC, VU University Medical Center
    Full Title: Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable T3-4N0-1 NSCLC
    Medical condition: locally advanced non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005106-35 Sponsor Protocol Number: INTRUST Start Date*: 2018-12-21
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: PHASE I - II STUDY OF INTRATUMORAL URELUMAB COMBINED WITH NIVOLUMAB IN PATIENTS WITH SOLID TUMORS
    Medical condition: Advanced solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002540-33 Sponsor Protocol Number: IFCT-1701 Start Date*: 2017-12-15
    Sponsor Name:IFCT
    Full Title: A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small C...
    Medical condition: PD-L1 positive stage IV Non Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003030-24 Sponsor Protocol Number: EDEN-GOIRC-04-2016 Start Date*: 2017-05-24
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: “An open-label, randomized phase III study of Early switch maintenance vs DElayed second-line Nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-l...
    Medical condition: Advanced stage (IIIB/IV) squamous non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025124 Lung squamous cell carcinoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025125 Lung squamous cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000462-11 Sponsor Protocol Number: CA209-592 Start Date*: 2018-07-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080083 Advanced lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-004284-27 Sponsor Protocol Number: CA043-001 Start Date*: 2022-01-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
    Medical condition: Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC)...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004095-31 Sponsor Protocol Number: ModuLung Start Date*: 2015-07-13
    Sponsor Name:Freistaat Bayer respresented by University of Regensburg represented by Kaufmännischer Direktor
    Full Title: A prospective phase II, randomized multi-center trial of a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squ...
    Medical condition: locally advanced or metastatic NSCLC, who have progressed during or following a platinum-containing regimen.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000262-38 Sponsor Protocol Number: CA209-77T Start Date*: 2019-08-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolum...
    Medical condition: Resectable Stage II-IIIB Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003866-14 Sponsor Protocol Number: APX005M-002 Start Date*: 2019-02-28
    Sponsor Name:Apexigen, Inc.
    Full Title: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastati...
    Medical condition: Non-small Cell Lung Cancer and Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029514 Non-small cell lung cancer NOS LLT
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-004283-65 Sponsor Protocol Number: CA209-79X Start Date*: 2020-08-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum-Based Chemother...
    Medical condition: Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum- Based Chemotherapy and Anti-PD-1 (L1) Immunotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000693-18 Sponsor Protocol Number: BreakB5/CA209-7WF Start Date*: 2020-12-07
    Sponsor Name:University Hospital Regensburg
    Full Title: Breaking the big Five Barriers of Brain Metastasis (Break B5-BM NSCLC Trial): A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with ...
    Medical condition: non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003805-82 Sponsor Protocol Number: P/2019/451 Start Date*: 2020-03-05
    Sponsor Name:CHU de Besançon
    Full Title: UCPVax plus Nivolumab versus standard chemotherapy as second line therapy in advanced non-small cell lung cancer : a randomized non-comparative phase II trial
    Medical condition: lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005142-29 Sponsor Protocol Number: UC-0107/1718 Start Date*: 2018-08-30
    Sponsor Name:UNICANCER
    Full Title: PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer
    Medical condition: Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 or PD-L1 antagonist according to the European Marketing Authorisation in a first line or a second line
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002108-15 Sponsor Protocol Number: CA044-001 Start Date*: 2018-09-25
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase 1/2 Study of BMS-986310 Administered Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003543-11 Sponsor Protocol Number: 16-214-02 Start Date*: 2017-07-10
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Ad...
    Medical condition: Locally Advanced or Metastatic Solid Tumor Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001359-36 Sponsor Protocol Number: CA223-001 Start Date*: 2016-07-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I /II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refracto...
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000038-33 Sponsor Protocol Number: DF6002-001 Start Date*: 2021-08-25
    Sponsor Name:Dragonfly Therapeutics, Inc.
    Full Title: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monoth...
    Medical condition: Solid Tumor Melanoma NSCLC Triple-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005602-26 Sponsor Protocol Number: FL-101-2001 Start Date*: 2021-08-03
    Sponsor Name:Flame Biosciences
    Full Title: A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients with Surgically Resectable Non-Small Cell Lung Cancer
    Medical condition: Surgically resectable non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029517 Non-small cell lung cancer stage I PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004380-40 Sponsor Protocol Number: CA209-76U Start Date*: 2020-11-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab
    Medical condition: The study population will include participants diagnosed with metastatic melanoma, advanced/metastatic urothelial carcinoma (mUC), advanced hepatocellular carcinoma (HCC) in Part 1, and metastatic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 10 19:37:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA